Biodesix Inc. (BDSX) reported Q1 EPS of ($0.50), $0.07 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $6.5 million versus the consensus estimate of $6.45 million.
GUIDANCE:
Biodesix Inc. sees FY2022 revenue of $37.5-39.5 million, versus the consensus of $38.4 million.